Gland - In the concall Mr. Sadu said impact is due to syringe supply constraints, but in Reddys latest concall, they said there is no such issue experienced by them. (It is evident there is huge demand for syringes all over the world for vaccines ) How to understand these kind of statements (in terms of management honesty / integrity ) ?
Question asked in Hitesh bhai’s portfolio thread by @Rafi_Syed @hitesh2710
My thinking
Syringes required for different products are different
Gland uses (as I know famous BD syringes and device)
Some of them are glass syringes for specific measured doses
Some high viscosity medicine are difficult to inject (usually done by support staff) (some time at home)required some locking system and flanges proper holding
All this syringes and devices are preapproved by regulators so you cannot change overnight
Now coming to the Dr Reddy’s concall comment
They have only 15% revenue from injectable(how much prefilled syringes i don’t know) (how much in US market)and maybe having different products, even in previous calls of gland Pharma… Gland is making products for Dr Reddy’s
Just taking small statement out of context and making big on social media (twitter) is trending
personally I take it as personal bias of some analysts
Ultimately time will tell the truth
(Syringes supplied with ampules & muti dose vials are just commodities)
| Subscribe To Our Free Newsletter |
